RenovoRx, Inc.

NasdaqCM RNXT

RenovoRx, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024

RenovoRx, Inc. Gross Profit Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqCM: RNXT

RenovoRx, Inc.

CEO	Mr. Shaun R. Bagai
IPO Date	Aug. 26, 2021
Location	United States
Headquarters	4546 El Camino Real
Employees	8
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Key trends

Past 5 years